[1]史 敏,郭晓波,李思远,等.结直肠癌患者组织中K-ras和BRAF基因突变与不同病理特征的相关性分析[J].现代检验医学杂志,2018,33(03):27-30.[doi:10.3969/j.issn.1671-7414.2018.03.009]
　SHI Min,GUO Xiao-bo,LI Si-yuan,et al.Correlation of K-ras and BRAF Mutations with Pathological Features in Patients with Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):27-30.[doi:10.3969/j.issn.1671-7414.2018.03.009]
点击复制

结直肠癌患者组织中K-ras和BRAF基因突变与不同病理特征的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年03期
页码:
27-30
栏目:
论著
出版日期:
2018-07-17

文章信息/Info

Title:
Correlation of K-ras and BRAF Mutations with Pathological Features in Patients with Colorectal Cancer
文章编号:
1671-7414(2018)03-027-04
作者:
史 敏1; 郭晓波2; 李思远3; 孟婷婷1; 尚丛珊1
1.西安培华学院医学院,西安 710125; 2.西安市中心医院,西安 710003; 3.西安交通大学第二附属医院,西安 710004
Author(s):
SHI Min1; GUO Xiao-bo2; LI Si-yuan3; MENG Ting-ting1; SHANG Cong-shan1
1.Xi'an Peihua University Medical College,Xi'an 710125,China; 2.Xi'an Central Hospital,Xi'an 710003,China; 3.the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China
关键词:
结直肠癌;  基因突变;  K-ras基因;  BRAF基因;  基因突变靶点
分类号:
R735.3; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.03.009
文献标志码:
A
摘要:
目的 分析K-ras基因、BRAF基因突变在结直肠癌(CRC)不同病变中的特点,从而探索CRC基因治疗的靶点。方法 采用实时荧光定量PCR法检测130例CRC患者肿瘤标本的K-ras基因、BRAF基因突变情况,并按不同的临床特征进行分析。结果 K-ras基因突变率在所有CRC患者中为36.15%(47/130),其在直肠癌患者中的突变率明显高于结肠癌患者[47.62%(30/63)vs 25.37%(17/67)],差异有统计学意义(χ2= 6.691,P<0.01),直肠癌患者Gly12ASP位点的突变率显著高于结肠癌患者[46.03%(29/63)vs 26.87%(20/67)],差异有统计学意义(χ2= 5.167,P<0.05); 在Ⅰ+Ⅱ期CRC患者中的突变率显著低于Ⅲ+Ⅳ期CRC患者[15.28%(11/72)vs 62.07%(36/58)],差异有统计学意义(χ2= 30.469,P=0.000)。BRAF基因突变率在所有CRC患者中为6.92%(9/130),其在结肠癌患者中的突变率明显高于直肠癌患者[11.94%(8/67)vs 1.59%(1/63),使用Fisher确切概率法P<0.05]; BRAF基因突变率在CRC患者术前血清CA199水平升高者明显高于水平正常者[11.59%(8/69)vs 1.64%(1/61),使用Fisher确切概率法P<0.05]。K-ras基因突变率与具体的病理学特征如性别、年龄、组织学分型等无统计学相关性(P>0.05)。结论在CRC患者中,K-ras基因突变较BRAF基因突变更为常见,且直肠癌患者较结肠癌患者更易表现为K-ras基因突变; K-ras基因突变率越高,CRC患者的TNM分期就越高; K-ras基因上Gly12ASP位点的突变与直肠癌的发生发展密切相关,血清CA199水平可作为BRAF基因突变的标志性物质。K-ras和BRAF基因突变靶点的相关研究有望为CRC的分子靶向治疗提供有力的理论支持。
Abstract:
Abstract:Objective To analyze the characteristics of K-ras and BRAF mutations in different lesions of colorectal cancer(CRC)so as toexplore the target of CRC gene therapy.Methods Detectionof K-ras and BRAF mutation in cancer samples from 130 CRC patients with real-time fluorescent quantitative PCR,and analyzed the gene mutation characteristics.Results The K-ras mutation rate was 36.15%(47/130)in all CRC patients,and its mutation rate in patients with rectal cancer was significantly higher than that in patients with colon cancer [47.62%(30/63)vs25.37%(17/67)],the difference was statistically significant(χ2= 6.691,P<0.01).The mutation rate of Gly12ASP in patients with rectal cancer was significantly higher than that in patients with colon cancer [46.03%(29/63)vs26.87%(18/67)],the difference was statistically significant(χ2=5.167,P<0.05).The mutation rate in stage Ⅰ+Ⅱ CRC patients was significantly lower than that in stage Ⅲ+Ⅳ CRC patients [15.28%(11/72)vs 62.07%(36/58)],the difference was statistically significant(χ2= 30.469,P=0.000).BRAFmutation rate was 6.92%(9/130)in all patients with CRC,and its mutation ratein patients with colon cancer was significantly higher than that in patients with rectal cancer [11.94%(8/67)vs 1.59%(1/63)by fisher exact probability method,P<0.05].The mutation rate of BRAF in patients with CRC elevated serum CA199 levels preoperatively was significantly higher than the level of normal[11.59%(8/69)vs 1.64%(1/61)by fisher exact probability method,P<0.05].K-ras mutation rate was not statistically related to specific pathologicalfeatures such as gender,age,histological type,etc(P>0.05).Conclusion In patients with CRC,K-ras mutation was more common thanBRAF mutation.Patients with rectal cancer were more likely to have K-ras mutation than colon cancer,and the higher the K-ras mutation rate,the higher theTNM stage of patients with CRC.The mutation of Gly12ASP on K-ras was closely related to the occurrence and development of rectal cancer.The serum CA199 levelcan be used as a marker for BRAF mutation.The related studies on K-ras and BRAF mutation targets are expected to provide powerful theoretical support for molecular targeted therapy for CRC.

参考文献/References:

[1] Siegel R,Desantis C,Jemal A. Colorectal cancer statistics,2014[J].CA:A Cancer J Clin,2014,64(2):104-117.
[2] 吴 奇,申高飞,孙丽娜,等.miR-181d在结肠癌中表达失调并抑制癌细胞增殖及凋亡[J].现代检验医学杂志,2017,32(2):15-18,22. Wu Q,Shen GF,Sun LN,et al.miR-181d inhibits proliferation and promotes apoptosis in colon cancer cells[J].Journal of Modern Laboratory Medicine,2017,32(2):15-18,22.
[3] 白盈盈,朱光旭,潘兴华.长链非编码RNA对结直肠癌潜在诊断价值的研究进展[J].现代检验医学杂志,2018,33(1):161-164. Bai YY,Zhu GX,Pan XH.The progress of the potential diagnostic value of long-chain non-coding RNA in colorectal cancer[J].Journal of Modern Laboratory Medicine,2018,33(1):161-164.
[4] 王钦君,张红春,申娴娟,等.MicroRNAs作为结直肠癌潜在标记物的研究进展[J].现代检验医学杂志,2015,30(4):107-110,114. Wang QJ,Zhang HC,Shen XJ,et al.MicroRNAs as a potential marker in the progress of colorectal cancer[J].Journal of Modern Laboratory Medicine,2015,30(4):107-110,114.
[5] Shadfan A,Hellebust A,Richards-Kortum R,et al.Confocal foveated endomicroscope for the detection of esophageal carcinoma[J].Biomed Opt Express,2015,6(7):2311-2324.
[6] 杨常顺.K-ras,BRAF基因在结直肠癌中突变特征及其临床意义[D].福州:福建医科大学,2014. Yang CS.The mutations of K-ras and BRAF gene in colorectal cancerand its clinical significance[D].Fuzhou:Fujian Medical University,2014.
[7] Ferlay J,Soerjomataram I,Ervik M,et al.GLOBOCAN 2012 v1.1,cancer incidence and mortality world-wide:IARC cancer base NO.11[J].International Journal of Caner Journal,2014,136(5):E359-E386.
[8] 张 凯,顾滕振.结直肠癌组织K-ras,BRAF及PIK 3CA基因突变的检测及其与临床病理特征的关系[J].广西医科大学学报,2016,33(2):299-301. Zhang K,Gu TZ.Detection of K-ras,BRAF and PIK3CA gene mutationsin colorectal cancer and their relationship with clinicopathological features[J].Journal of Guangxi Medical University,2016,33(2):299-301.
[9] 陈建国.结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的研究[J].现代检验医学杂志,2016,31(5):66-68,72. Chen JG.Relationship between FOLFOX chemotherapy of colorectal cancer patients and GSTP1,XRCC1 gene polymorphism[J].Journal of Modern Laboratory Medicine,2016,31(5):66-68,72.
[10] 涂露霞,万红萍,熊 磊,等.结直肠癌BRAF和K-ras基因状态及其病理意义[J].广东医学,2014,35(21):3368-3371. Tu LX,Wan HP,Xiong L.BRAF and K-ras status and its pathological significance in colorectal cancer[J].Guangdong Medical Journal,2014,35(21):3368-3371.
[11] 姚 晖,汪杰华,李 莉,等.560例中国结直肠癌患者K-ras基因突变研究[J].国际检验医学杂志,2016,37(19):2715-2717. Yao H,Wang JH,Li L,et al.Analysis of K-ras gene mutation status in 560 Chinese colorectal cancer patients[J].International Journal of Laboratory Medicine,2016,37(19):2715-2717.
[12] 祝继原,吴 鹤,张 振,等.K-ras基因突变与结直肠癌临床病理特征的相关性研究[J].现代生物医学进展,2016,16(35):6848-6851. Zhu JY,Wu H,Zhang Z,et al.Correlative research of K-ras gene mutationwith the clinical pathological features of colorectal cancer[J].Progress inModern Biomedicine,2016,16(35):6848-6851.

相似文献/References:

[1]张 莉,黄伟忠,唐景云,等.深圳市珠蛋白生成障碍性贫血流行病学调查及基因突变类型与频率分析[J].现代检验医学杂志,2015,30(04):71.[doi:10.3969/j.issn.1671-7414.2015.04.019]
　ZHANG Li,HUANG Wei-zhong,TANG Jing-yun,et al.Epidemiological and Gene Mutation Type and Frequency Analysis of Thalassaemia in Shenzhen[J].Journal of Modern Laboratory Medicine,2015,30(03):71.[doi:10.3969/j.issn.1671-7414.2015.04.019]
[2]韩光宇,徐 湛,李全双,等.DNA微阵列芯片法检测遗传性耳聋基因[J].现代检验医学杂志,2016,31(04):47.[doi:10.3969/j.issn.16717-414.2016.04.012]
　HAN Guang-yu,XU Zhan,LI Quan-shuang,et al.Detection of Hereditary Hearing Loss Gene by DNA Microarray[J].Journal of Modern Laboratory Medicine,2016,31(03):47.[doi:10.3969/j.issn.16717-414.2016.04.012]
[3]陈建国.结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的研究[J].现代检验医学杂志,2016,31(05):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
　CHEN Jian-guo.Relationship between FOLFOX Chemotherapy of Colorectal Cancer Patients and GSTP1,XRCC1 Gene Polymorphism[J].Journal of Modern Laboratory Medicine,2016,31(03):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
[4]周秋媛,王红莉,李虹,等.NRP-1和NRP-2在结直肠癌组织中的表达水平及临床意义[J].现代检验医学杂志,2016,31(06):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
　ZHOU Qiu-yuan,WANG Hong-li,LI Hong,et al.Serum NRP-1 and NRP-2 Expression in Colorectal Cancer Patients and Its Relationship with Clinical Pathology[J].Journal of Modern Laboratory Medicine,2016,31(03):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
[5]张永庆a,尚立群a,苗 毅a,等.表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析[J].现代检验医学杂志,2017,32(06):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Yong-qinga,SHANG Li-quna,MIAO Yia,et al.Analysis of the Correlation between Mutations of the Epidermal Growth Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(03):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]井丰军,倪勇.结直肠癌患者外周血NLR与RDW的变化及临床意义[J].现代检验医学杂志,2018,33(03):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
　JING Feng-jun,NI Yong.Change and Significance of Neutrophil/Lymphocyte Ratio and Red Blood Cell Distribution Width of Peripheral Blood in the Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
[7]滕祥云,王新梦,刘　维,等.中国汉族结直肠癌患者 UGT1A1*28基因多态性分析[J].现代检验医学杂志,2019,34(06):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
　TENG Xiang-yun,WANG Xin-meng,LIU Wei,et al.Polymorphism of UGT1A1*28 Gene in Han Patients with Colorectal Cancer in China[J].Journal of Modern Laboratory Medicine,2019,34(03):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
[8]陈 培,邓钦木,李丹丹.血浆Septin9 甲基化检测在结直肠癌中的诊断价值[J].现代检验医学杂志,2020,35(04):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
　CHEN Pei,DENG Qin-mu,LI Dan-dan.Diagnostic Value of Plasma Septin9 Methylation in Screening of Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
[9]杨婕琳a,陈文婷b,胡晓利a.结直肠癌组织中硫氧还蛋白-1与硫氧还蛋白互作蛋白的表达及其临床意义[J].现代检验医学杂志,2021,36(06):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
　YANG Jie-lin,CHEN Wen-ting,HU Xiao-li.Expression and Clinical Significance of Thioredoxin-1 and Thioredoxin Interacting Protein in Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
[10]马胜辉,崔雪琴,李建华,等.结直肠癌组织miR-485-5p，miR-1207-3p和miR-590-3p水平表达与临床病理特征及生存的相关性研究[J].现代检验医学杂志,2022,37(03):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]
　MA Sheng-hui,CUI Xue-qin,LI Jian-hua,et al.Correlation of miR-485-5p, miR-1207-3p, miR-590-3p Level Expression and Clinicopathologic Characteristics and Survival in Colorectal Cancer Tissue[J].Journal of Modern Laboratory Medicine,2022,37(03):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]

备注/Memo

备注/Memo:
基金项目:国家青年科学基金项目(项目批准号:31300675)。 作者简介:史 敏(1982-),女,硕士,讲师,研究方向:病理学及病理生理学研究,E-mail:1243838277@qq.com。 通讯作者:郭晓波(1981-),男,副主任检验师,研究方向:分子生物学,E-mail:258442579@qq.com。
更新日期/Last Update: 2018-04-16